Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
AQST
AQST
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
AQST News
Faruqi & Faruqi Investigates Investor Losses in Aquestive Therapeutics
2d ago
PRnewswire
Pomerantz LLP Investigates Securities Fraud Claims Against Aquestive Therapeutics
2d ago
PRnewswire
Faruqi & Faruqi Investigates Aquestive Therapeutics After FDA Concerns
Feb 07 2026
PRnewswire
Faruqi & Faruqi Investigates Aquestive Therapeutics' FDA Issues
Feb 04 2026
Globenewswire
Pomerantz LLP Investigates Fraud Claims Against Aquestive Therapeutics
Feb 03 2026
Globenewswire
Aquestive Therapeutics Shares Surge 39% Despite FDA Complete Response Letter
Feb 02 2026
seekingalpha
Aquestive Therapeutics Receives Complete Response Letter from FDA
Feb 02 2026
Benzinga
Schall Law Firm Investigates Aquestive for Securities Violations
Feb 02 2026
Businesswire
Aquestive Therapeutics Stock Soars 43% Following FDA Complete Response Letter
Feb 02 2026
NASDAQ.COM
Aquestive Therapeutics Receives FDA Response Progress
Feb 02 2026
stocktwits
Brookfield to Acquire Peakstone Realty Trust for $1.2 Billion
Feb 02 2026
Benzinga
Aquestive Advances Anaphylm Drug Approval Process Following FDA Feedback
Feb 02 2026
Newsfilter
Faruqi & Faruqi Investigates Losses in Aquestive Therapeutics
Jan 29 2026
PRnewswire
Faruqi & Faruqi Urges Investors to Discuss Losses in Aquestive Therapeutics
Jan 26 2026
PRnewswire
Faruqi & Faruqi Investigates Aquestive Therapeutics' FDA Application Deficiencies
Jan 23 2026
Globenewswire
Bragar Eagel & Squire Investigates Potential Claims Against Aquestive (AQST)
Jan 20 2026
Globenewswire
Show More News
